U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07793253) titled 'Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer' on Aug. 25.
Brief Summary: The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic therapy.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Biliary Tract Cancers
Intrahepatic Cholangiocarcinoma (Icc)
Extrahepatic Cholangiocarcinoma
Gallbladder Carcinoma
Ampulla of Vater Carcinoma
Ampullary Carcinoma
Intervention:
DRUG: Daraxonrasib
Daraxonrasib will be taken at a do...